Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 3, 2008, Pages 348-351

  Niwa, Toshiro ^a   Okada, Kazushi ^a,b   Hiroi, Toyoko ^a   Imaoka, Susumu ^b   Narimatsu, Shizuo ^c   Funae, Yoshihiko ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KWANSEI GAKUIN UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Allopregnanolone 21 hydroxylation; Cytochrome P450 2D4; Cytochrome P450 2D6; Fluoxetine; Progesterone 21 hydroxylation; Psychotropic drug

Indexed keywords

21 HYDROXYALLOPREGNANOLONE; CYTOCHROME P450 2D; CYTOCHROME P450 2D4; CYTOCHROME P450 2D6; DEOXYCORTICOSTERONE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MAZINDOL; NEUROSTEROID; UNCLASSIFIED DRUG; VANOXERINE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG COMPETITION; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; NONHUMAN; STEROID METABOLISM; TANDEM MASS SPECTROMETRY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN; CATALYSIS; CLONING, MOLECULAR; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MICROSOMES; PREGNANOLONE; PROGESTERONE; PSYCHOTROPIC DRUGS; RATS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SUBSTRATE SPECIFICITY;

EID: 41149176900     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.348     Document Type: Article

References (40)

1. Baurieu E. E., Psychoneuroendocrinology, 23, 963-987 (1998).
2. Wu F. S., Gtibbs T. T., Farb D. H., Mol. Pharmacol., 37, 597-602 (1990).
3. Jung-Testas I., Do Thi A., Koenig H., Desarnaud F., Shazand K., Schumacher M., Baulieu E. E., J. Steroid Biochem. Mol. Biol., 69, 97-107 (1999).
4. Paul S. M., Purdy R. H., FASEB J., 6, 2311-2322 (1992).
5. Funae Y., Kishimoto W., Cho T., Niwa T., Hiroi T., Drug Metab. Pharmacokin., 18, 337-349 (2003).
6. Gonzales F. J., Pharmacol. Ther., 45, 1-38 (1990).
7. Guengerich F. P., FASEB J., 6, 745-748 (1992).
8. Rendic S., Drug Metab. Rev., 34, 83-448 (2002).
9. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P., J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
10. Imaoka S., Yamada T., Hiroi T., Hayashi K., Sakaki T., Yabusaki Y., Funae Y., Biochem. Pharmacol., 51, 1041-1050 (1996).
11. Cholerton S., Daly A. K., Idle J. R., Trends Pharmacol. Sci., 13, 434-439 (1992).
12. Niwa T., Shiraga T., Mitani Y., Terakawa M., Tokuma Y., Kagayama A., Drug Metab. Dispos., 28, 1128-1134 (2000).
13. McFadyen M. C. E., Melvin W. T., Murray G. I., Biochem. Pharmacol., 55, 625-830 (1998).
14. Hiroi T., Imaoka S., Chow T., Funae Y., Biochim. Biophys. Acta, 1380, 305-312 (1998).
15. Kishimoto W., Hiroi T., Shiraishi M., Osada M., Imaoka S., Kominami S., Igarashi T., Funae Y., Endocrinology, 145, 699-705 (2004).
16. Komori M., Biochem. Biophys. Res. Commun., 196, 721-728 (1993).
17. Niwa T., Yabusaki Y., Honma K., Matsuo N., Tatsuta K., Ishibashi F., Katagiri M., Xenobiotica, 28, 539-547 (1998).
18. Hiroi T., Kishimoto W., Chow T., Imaoka S., Igarashi T., Funae Y., Endocrinology, 142, 3901-3908 (2001).
19. Brosen K., Zeugin T., Meyer U. A., Clin. Pharmacol. Ther., 49, 609-617 (1991).
20. Hiemke C., Hartter S., Pharmacol. Ther., 85, 11-28 (2000).
21. Shin J., Park J., Kim M., Shon J., Yoon Y., Cha I., Lee S., Oh S., Kim S., Flockhart D. A., Drug Metab. Dispos., 30, 1102-1107 (2002).
22. Niwa T., Shiraga T., Ishii I., Kagayama A., Takagi A., Biol. Pharm. Bull., 28, 1711-1716 (2005).
23. Mandrioli R., Forti G. C., Raggi M. A., Curr. Drug Metab., 7, 127-133 (2006).
24. Reith M. E. A., Sershen H., Lajtha A., Life Sci., 27, 1055-1062 (1980).
25. Javitch J. A., Blaustein R. O., Snyder S. H., Eur. J. Pharmacol., 106, 455-456 (1983).
26. Andersen P. H., J. Neurochem., 48, 1887-1896 (1987).
27. Niznik H. B., Tyndale R. F., Sallee F. R., Gonzalez F. J., Hardwick J. P., Inaba T., Kalow W., Arch. Biochem. Biophys., 276, 424-432 (1990).
28. Hiroi T., Imaoka S., Chow T., Yabusaki Y., Funae Y., Biochem. Pharmacol., 53, 1937-1939 (1997).
29. Niwa T., Hiroi T., Tsuzuki D., Yamamoto S., Narimatsu S., Fukuda T., Azuma J., Funae Y., Mol. Brain Res., 129, 117-123 (2004).
30. Akaike H., Transact. Automat. Control, 19, 716-723 (1974).
31. Henry M. E., Schmidt M. E., Hennen J., Villafuerte R. A., Butman M. L., Tran P., Kerner L. T., Cohen B., Renshaw P. F., Neuropsychopharmacology, 30, 1576-1583 (2005).
32. Barkai A. I., Suckow R. F., Cooper T. B., J. Pharmacol. Exp. Ther., 230, 330-335 (1984).
33. Holladay J. W., Dewey M. J., Yoo S. D., Drug Metab. Dispos., 26, 20-24 (1998).
34. Hendset M., Haslemo T., Rudberg I., Refsum H., Molden E., Pharmacopsychiatry, 39, 121-127 (2006).
35. Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R., Biochemistry, 33, 6450-6455 (1994).
36. Hollenberg P. F., Drug Metab. Rev., 34, 17-35 (2002).
37. Niwa T., Shiraga T., Yamasaki S., Ishibashi K., Ohno Y., Kagayama A., Xenobiotica, 33, 717-729 (2003).
38. Ball S. E., Ahern D., Scatina J., Kao J. Br. J. Clin. Pharmacol., 43, 619-626 (1997).
39. Cherstniakova S. A., Bi D., Fuller D. R., Mousiak J. Z., Collins J. M., Cantilena L. R., Drug Metab. Dispos., 29, 1216-1220 (2001).
40. Newton D. J., Wang R. W., Lu A. Y. H., Drug Metab. Dispos., 23, 154-158 (1995).